<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827030</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2020-04</org_study_id>
    <nct_id>NCT04827030</nct_id>
  </id_info>
  <brief_title>ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery</brief_title>
  <acronym>ER-One</acronym>
  <official_title>A Double-blind Randomized Non-inferiority Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery: Effects on Acute Postoperative Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The block (ESP or PVB) will be performed preoperatively in the recovery room under standard&#xD;
      monitoring. After setting a peripheral venous access, patient will be installed on lateral&#xD;
      decubitus position on the opposite side of the block.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The block will be performed with IV Remifentanil sedation Target-Controlled Infusion mode at&#xD;
      2ng/ml and oxygen therapy.&#xD;
&#xD;
      For the erector spinae plane block:&#xD;
&#xD;
      The puncture will be performed with ultrasound guidance. The ultrasound probe will be placed&#xD;
      parallel to the spine parasagittally at the T3 transverse process level. The needle will be&#xD;
      introduced and visualized to the plane of the ultrasound image (&quot;in plane&quot;).&#xD;
&#xD;
      The desired injection site is between the fascia of the erector muscle of the spine and the&#xD;
      transverse process at the T3 level. The operator ensures the correct localization of the&#xD;
      needle with saline solution. Then 0.50% Ropivacaine hydrochloride will be injected at a dose&#xD;
      of 0.6 ml/kg of actual weight, without exceeding 30 ml.&#xD;
&#xD;
      For paravertebral block:&#xD;
&#xD;
      The T2 intervertebral space will be located by identifying compared to C7, a prominent&#xD;
      cervical vertebra, or by ultrasound by counting the thoracic vertebrae from the first rib.&#xD;
      The paravertebral space will be identified by placing the ultrasound probe in a parasagittal&#xD;
      or transverse position. The needle will go through the paravertebral muscles and the&#xD;
      costo-transverse ligament or by a latero-medial approach using ultrasound. The block will be&#xD;
      performed using a 22-gauge 8cm long needle. When the paravertebral space has been reach, an&#xD;
      aspiration test will be performed and then 0.6 ml/kg of solution (Ropivacaine hydrochloride&#xD;
      solution at 5 mg/ml up to 30 ml) will be injected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Double-blind Randomized non-inferiority Trial of erector spinae block (ESP) versus paravertebral block (PVB)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of ESP versus PVB on acute postoperative pain</measure>
    <time_frame>24 hours</time_frame>
    <description>Percentage of patients needed morphine during the first two postoperative hours in each treatment arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative morphine consumption</measure>
    <time_frame>2 hours</time_frame>
    <description>Dose of opioid, in the Post-Anesthesia Care Unit (PACU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of remifentanil in the Operating Room (OR)</measure>
    <time_frame>During the period from the surgical incision to the end of the surgical dissection</time_frame>
    <description>Dose of Remifentanil during the Operating Room (OR) period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute early postoperative pain by Visual Analog Scale (VAS)</measure>
    <time_frame>24 hours</time_frame>
    <description>VAS (no pain=0, worst pain=10) at arrival in the PACU, every 30 minutes in the Post-Anaesthesia Care Unit (PACU), VAS at 4 and 24 hours. Pain scores will be evaluated at rest and after shoulder movement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of nausea or vomiting</measure>
    <time_frame>2 hours</time_frame>
    <description>Number of patient who related nausea or vomiting side effects will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of complications and side effects of each block</measure>
    <time_frame>30 days</time_frame>
    <description>Complications and side effects of each block will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative extend of dermatomes blocked</measure>
    <time_frame>2 hours</time_frame>
    <description>The extent of dermatomes blocked as measured by clinical examination to determine area where temperature perception change</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">292</enrollment>
  <condition>Breast Surgery</condition>
  <arm_group>
    <arm_group_label>Ropivacaine hydrochloride injected by Erector Spinae block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine hydrochloride injected by Paravertebral block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The injection will be performed with Ropivacaine hydrochloride 0.6 ml/kg of solution at 5 mg/ml up to 30 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaïne Hydrochloride by Erector Spinae block</intervention_name>
    <description>Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.</description>
    <arm_group_label>Ropivacaine hydrochloride injected by Erector Spinae block</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaïne Hydrochloride by Paravertebral block</intervention_name>
    <description>Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.</description>
    <arm_group_label>Ropivacaine hydrochloride injected by Paravertebral block</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Woman with breast adenocarcinoma without metastasis or breast in situ adenocarcinoma&#xD;
             (with or without breast reconstruction by prosthesis) to by treated:&#xD;
&#xD;
               -  either by breast-conserving surgery with axillary dissection,&#xD;
&#xD;
               -  either by modified radical mastectomy with axillary dissection&#xD;
&#xD;
               -  either by modified radical mastectomy with lymph node dissection&#xD;
&#xD;
               -  either by modified radical mastectomy without axillary&#xD;
&#xD;
          2. Patients aged between 18 and 85 years old.&#xD;
&#xD;
          3. ASA class 1, 2 or 3 (Physical Status Classification System of American Society of&#xD;
             Anesthesiologists (ASA)).&#xD;
&#xD;
          4. Signed informed consent form.&#xD;
&#xD;
          5. Patient able to answer self-assessment questionnaires (sufficient understanding of&#xD;
             evaluations and in French).&#xD;
&#xD;
          6. Patient affiliated to the health care insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Preoperative consumption of opioid in the patient's current medications within three&#xD;
             months before inclusion.&#xD;
&#xD;
          2. Ipsilateral breast surgery during 3 months prior to the inclusion.&#xD;
&#xD;
          3. Allergy to local anaesthetics and morphine and NSAID.&#xD;
&#xD;
          4. Local skin inflammation at the puncture area.&#xD;
&#xD;
          5. Bilateral breast surgery planned at inclusion.&#xD;
&#xD;
          6. Major immediate ipsilateral breast reconstruction by using tissue flap procedure&#xD;
             (example: latissimus dorsi flap, Deep Inferior Epigastric Perforator (DIEP),&#xD;
             Transverse Rectus Abdominis Musculocutaneous (TRAM)…).&#xD;
&#xD;
          7. Any contra-indication or patient's refusal for regional anesthesia.&#xD;
&#xD;
          8. Male subjects.&#xD;
&#xD;
          9. Pregnant woman or breastfeeding.&#xD;
&#xD;
         10. B blocker medication.&#xD;
&#xD;
         11. Patient already participating in an analgesia protocol that may interfere with the&#xD;
             pain assessment criteria.&#xD;
&#xD;
         12. Patient under legal protection.&#xD;
&#xD;
         13. Inability to undergo medical monitoring of the trial for geographical, social or&#xD;
             psychological reasons.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre FUMOLEAU, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julien RAFT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aline ALBI-FELDZER, MD</last_name>
    <phone>+33 1 47 11 15 15</phone>
    <email>aline.albi-feldzer@curie.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle TURBIEZ</last_name>
    <phone>+ 33 1 56 24 56 30</phone>
    <email>drci.promotion@curie.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre GAYRAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre GAYRAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrien LEMOINE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adrien LEMOINE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aline ALBI-FELDZER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aline ALBI-FELDZER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud UICT</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régis FUZIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Régis FUZIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien RAFT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julien RAFT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Surgery</keyword>
  <keyword>anaesthetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

